FDA rejects a migraine drug over manufacturing concerns; Novartis, Veolia ink a $1.3B services deal;

> The FDA has sent a complete response letter to Israel's RedHill Biopharma and Canada's IntelGenx, rejecting their migraine drug over concerns about the contract manufacturing process involved, as well as packaging and labeling. Story

> Novartis ($NVS) has expanded a 5-year, $1.25 billion contract with French waste and water management company Veolia Environment to supply water and energy and collect and treat hazardous and other waste at 15 sites. Report

> Sagent Pharmaceuticals ($SGNT) has launched its National Research Center in Chengdu, China, which will work on developing "technically challenging specialty injectable pharmaceuticals" to be manufactured at its plant there. Release (pdf)

> Forest Laboratories has completed its $2.9 billion purchase of Aptalis, a company that focuses on treatments for gastrointestinal problems and cystic fibrosis. Story

> VWR International has a deal to buy Peqlab Biotechnologie, which develops, manufactures and supplies molecular and cell biology reagents and other products. Report

And Finally... After a huge contraction in 2012, drug spending in Spain is again on the rise. Story